Andrew Huberman

Consumer health shifted from a vanity niche to a self-directed mass market when mainstream fitness collided with COVID-era mortality and distrust. Vitamin D, resistance training, protein, caffeine and creatine became rungs on an adoption ladder; the behavioral reset was, “We are all responsible for our own health.”

GLP-1s may turn healthy weight from evidence of disciplined exercise into an accessible baseline, much as credit made decent cars broadly available. Daisy Wolf says nearly one in seven Americans takes one and 20% have tried them; Huberman predicts more than half could be users within five years, often at lower doses. Retatrutide, which he says went through phase three at Lilly, can produce up to one-third body-weight loss with some muscle sparing: “In theory, you could eradicate obesity.”

The peptide boom is outrunning regulated distribution, making price, access, purity and evidence separate market variables. Pharma products can cost three to 10 times more; compounding pharmacies, gray-market “research” vendors and black-market sellers offer progressively weaker assurances. Huberman’s conclusion is that “the horse is out of the stable,” though Daisy flags contamination or a meningitis outbreak as concerns with less-regulated compounding.

Demand is being pulled by unusually vivid benefits, but the same mechanisms make safety failures potentially severe. BPC-157 might accelerate tissue repair while vascularizing an unseen tumor; growth-hormone secretagogues increase deep sleep, growth hormone and IGF-1; Huberman describes melanotan as raising libido and energy and causing dramatic fat loss, while warning of permanent pigmentation changes. Daisy warns that men can experience priapism that may damage nerves and penile tissue. “You have to be real careful with these things.”

Sleep and metabolic care may move from wearables that merely read biology to devices and drugs that write it in real time. Huberman imagines palm or foot cooling, an eye mask that induces sleep within six minutes, 10,000-lux waking light and continuous cortisol sensing. A strong morning cortisol pulse followed by an afternoon trough is, in his telling, “90% of the game.”

Focus remains a large unmet need, but current drugs mostly rent alertness from sleep and cardiovascular reserve rather than increasing focus itself. Modafinil, Ritalin, Adderall, nicotine and low-dose Wellbutrin are used for alertness or focus; Sunosi may provide a gentler arc, but Huberman found it excessive. “You always pay the piper somehow,” through impaired sleep or cardiac challenges.

AI can commoditize health checklists and diagnosis, but Huberman thinks mechanism-rich teaching may remain the behavior-change moat. Daisy expects models combining EHRs, wearables, blood tests and imaging to detect problems before symptoms; Huberman uses Claude to quiz himself but argues people comply better when they understand why a protocol works.

Longevity escape velocity looks implausible to Huberman, while regenerative proteins and banking one’s own exercised blood look nearer-term. He puts the genetic upper limit near 120 and probably closer to 105 for most people—“Aim for 100 healthy”—and says he would bank his healthier blood at 50 for possible use later. Daisy says she gets glutathione and NAD infusions but is unsure how much they provide.

🔗 Original source & video: Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity